Procter & Gamble Health Ltd Rated Hold Amid Expensive Valuation
Procter & Gamble Health Ltd has been rated 'Hold' by MarketsMojo as of August 15, 2026. This rating suggests that while the stock may not offer significant upside potential in the near term, it remains a stable investment with moderate risk.
The Hold rating is based on four key parameters: Quality, Valuation, Financial Trend, and Technicals. Procter & Gamble Health Ltd demonstrates high management efficiency, reflected in a robust Return on Equity (ROE) of 36.14%. The company is also net-debt free, which strengthens its financial stability and reduces risk exposure.
However, the stock is currently rated as very expensive on valuation metrics, with a Price to Book Value of 15.9 and a PEG ratio of 2.7. These figures indicate that investors are pricing in strong future growth or premium brand value. The company's financial trend is also flat, with net sales growing at an annualised rate of 7.27% over the past five years.
Despite these concerns, Procter & Gamble Health Ltd offers a relatively attractive dividend yield of 3.4%, which may appeal to income-focused investors. From a technical perspective, the stock is rated as mildly bullish, with recent price movements showing a 0.53% gain on the day.